The morcellation controversy heats up as physicians all over the world who use Ethicon power morcellators are being asked to return the medical devices.
Earlier this year, Johnson & Johnson’s Ethicon unit suspended sales and distribution of its power morcellators. J&J is now calling for “a worldwide market withdrawal” of any Ethicon morcellation devices, and they are asking their customers-physicians and hospitals-to return any and all of these devices that have already been purchased. The company is issuing a credit for all devices returned before December 30, 2014. (
to see the letter.)
J&J’s decision comes after the FDA has recommended that the use of these devices be suspended until further review of the risk of these devices inadvertently spreading an unknown cancer in women with fibroids.
"Due to this continued uncertainty, Ethicon believes that a market withdrawal of Ethicon morcellation devices is the appropriate course of action at this time until further medical guidelines are established and/or new technologies are developed to mitigate the risk," the company said in an e-mailed statement to Reuters, as reported in this Huffington Post article.
How will this impact your practice, and what do you think about this recall?
(We invite you to share your thoughts in the Comment Section below.)
Unlocking placenta accreta spectrum with single-cell gene targets
April 18th 2024Discover how cutting-edge single-cell RNA sequencing unveils molecular insights into placenta accreta spectrum disorders, potentially revolutionizing diagnostics and treatments for this life-threatening pregnancy complication.
Read More
Excessive gonadotropins in IVF: Effects on mosaicism and live birth
April 12th 2024A recent study revealed a correlation between high doses and prolonged duration of exogenous gonadotropin use during in vitro fertilization and increased embryonic mosaicism alongside diminished live birth rates, prompting reconsideration of dosage and duration protocols.
Read More
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More